Jan‐Christoph Simon

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

Ulrike Leiter, Rudolf Stadler, Cornelia Mauch et al. · The Lancet Oncology · 2016 · 700 citations

Medicine, Oncology, Surgery +11

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

The LIFE-Adult-Study: objectives and design of a population-based cohort study with 10,000 deeply phenotyped adults in Germany

Markus Loeffler, Christoph Engel, Peter Ahnert et al. · BMC Public Health · 2015 · 374 citations · Full text

Public Health, Geriatric Medicine, Population Health Sciences +14

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node

Ulrike Leiter, Rudolf Stadler, Cornelia Mauch et al. · Journal of Clinical Oncology · 2019 · 246 citations

Medicine, Dermatology, Oncology +17

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel et al. · The Lancet · 2020 · 242 citations

Medicine, Immunology, Oncology +14